Genomic analysis as the first step toward personalized treatment in renal cell carcinoma

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Bielecka, Zofia F ^a,b   Czarnecka, Anna M ^a   Szczylik, Cezary ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Genome wide analysis; Genomics; High throughput techniques; Personalized treatment; Prognostic and predictive biomarkers; Renal cell carcinoma; Translational research; Tumor heterogeneity

Indexed keywords

3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; BETA TUBULIN; BIOLOGICAL MARKER; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CD31 ANTIGEN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR; INTERLEUKIN 2; INTERLEUKIN 8; LACTATE DEHYDROGENASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; OSTEOPONTIN; PROTEIN SERINE THREONINE KINASE; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; SCATTER FACTOR; SMALL INTERFERING RNA;

ARTICLE; BIRT HOGG DUBE SYNDROME; CANCER IMMUNOTHERAPY; CELL HETEROGENEITY; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENOME ANALYSIS; HUMAN; KIDNEY CARCINOMA; MOLECULARLY TARGETED THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC ACQUIRED RESISTANCE; TUMOR SUPPRESSOR GENE;

EID: 84904660221     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00194     Document Type: Article

References (150)

1. Pascual D, Borque A. Epidemiology of kidney cancer. Adv Urol 2008: 782381
2. McRonald FE, Morris MR, Gentle D et al. CpG methylation profiling in VHL related and VHL unrelated renal cell carcinoma. Mol Cancer 2009; 8:31. Epub 2009/06/06
3. Seizinger BR, Rouleau GA, Ozelius LJ et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 1988; 332(6161):268-9
4. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. WHO-World Health Organization: Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Iarc Press 2004;7:359
5. Von Hippel E (1904). "Ueber eine sehr seltene Erkrankung der Netzhaut". Albrecht von Graefes Arch Ophthal 59: 83-106.
6. Lindau A. Studien über Kleinhirncysten. Bau, Pathogenese und Beziehungen zur Angiomatosis retinae, (doctoral thesis); Acta pathologica et microbiologica Scandinavica, Copenhagen, 1926, 3 (supplement): 1-128.
7. Lindau A. Angiomatosis retinae. Acta pathologica et microbiologica Scandinavica, Copenhagen, 1926, supplement 1: 77.
8. Go RC, Lamiell JM, Hsia YE et al. Segregation and linkage analyses of von Hippel Lindau disease among 220 descendants from one kindred. Am J Hum Genet 1984;36(1): 131-42
9. Hosoe S, Brauch H, Latif F et al. Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3. Genomics 1990;8(4):634-40
10. Latif F, Tory K, Gnarra J et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993;260(5112):1317-20
11. Cohen D, Zhou M. Molecular genetics of familial renal cell carcinoma syndromes. Clin Lab Med. 2005;25(2): 259-77
12. Knudson AG. VHL gene mutation and clear-cell renal carcinomas. Cancer J Sci Am 1995; 1(3): 180-1
13. Gnarra JR, Tory K, Weng Y et al. Mutations of the VHL tumor suppressor gene in renal cell carcinoma. Nat Genet 1994(7):85-90
14. Maxwell PH1, Wiesener MS, Chang GW et al. The tumor suppressor protein VHL targets hypoxiainducible factors for oxygen-dependent proteolysis. Nature 1999;399:271-5
15. Maher ER. Genomics and epigenomics of renal cell carcinoma. Semin Cancer Biol 2013; 23(1): 10-7
16. Rydzanicz M, Wrzesinski T, Bluyssen HA, Wesoly J. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications. Cancer Lett 2013;341(2):111-26
17. Arsanious A, Bjarnason GA, Yousef GM. From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma. Mol Cancer 2009;8:20
18. Larkin J, Goh XY, Vetter M, Pickering L, Swanton C. Epigenetic regulation in RCC: opportunities for therapeutic intervention? Nat Rev Urol 2012;9(3):147-55
19. Su D, Stamatakis L, Singer EA, Srinivasan R. Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol 2014;26(3): 321-7
20. Varela I, Tarpey P, Raine K et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469(7331): 539-42
21. Hakimi AA, Chen YB, Wren J et al. Clinical and pathologic impact of select chromatin-modulating tumor suppressors in clear cell renal cell carcinoma. Eur Urol 2013;63(5): 848-54
22. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013;499(7456): 43-9
23. Kapur P, Peña-Llopis S, Christie A et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013;14(2): 159-67
24. Vasudev NS, Selby PJ, Banks RE. Renal cancer biomarkers: the promise of personalized care. BMC medicine 2012;10:112
25. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2(1):38-47
26. Zhang Z, Wondergem B, Dykema K. A Comprehensive Study of Progressive Cytogenetic Alterations in Clear Cell Renal Cell Carcinoma and a New Model for ccRCC Tumorigenesis and Progression. Adv Bioinformatics 2010; 2010: 428325
27. Pei J, Feder MM, Al-Saleem T et al. Combined Classical Cytogenetics and Microarray-based Genomic Copy Number Analysis Reveal Frequent 3;5 Rearrangements in Clear Cell Renal Cell Carcinoma. Genes Chromosomes Cancer 2010; 49(7): 610-619
28. Schmidt L, Duh FM, Chen F et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 1997;16(1): 68-73
29. Schmidt L, Junker K, Nakaigawa N et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene. 1999;18(14): 2343-50
30. Warburg O. On the origin of cancer cells. Science. 1956(123): 309-14
31. Dalgin GS, Holloway DT, Liou LS, DeLisi C. Identification and Characterization of Renal Cell Carcinoma Gene Markers. Cancer Informatics 2007;(3):65-92
32. Vocke CD, Yang Y, Pavlovich CP et al. High frequency of somatic frameshift BHD gene mutation in Birt-Hogg-Dubé-associated renal tumors. J Natl Cancer Inst 2005;(97): 931-5
33. Sun M, Shariat SF, Cheng C et al. Prognostic factors and predictive models in renal cell carcinoma: a contemporary review. European urology 2011;60(4):644-61. Epub 2011/07/12
34. Baba M, Hong SB, Sharma N et al. Folliculin encoded by the BHD gene interacts with a binding protein FNIP1 and AMPK and is involved in AMPK and mTOR signalling. Proceedings of the National Academy of Sciences of the United States of America 2008(103): 15552-7
35. Slater AA, Alokail M, Gentle D et al. DNA methylation profiling distinguishes histological subtypes of renal cell carcinoma. Epigenetics 2013;8(3):252-67
36. Boer JM, Huber WK, Sültmann H et al. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 2001;11(11): 1861-70
37. Young AN, Amin MB, Moreno CS et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001;158(5): 1639-51
38. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: Class discovery and class prediction by gene expression monitoring. Science 199;286: 531-537
39. Skubitz KM, Skubitz AP. Differential gene expression in renal-cell cancer. J Lab Clin Med 2002;140(1): 52-64
40. Higgins JP, Shinghal R, Gill H et al. Gene expression patterns in renal cell carcinoma assessed by complementary DNA microarray. Am J Pathol 2003;162(3): 925-32
41. Takahashi M, Yang XJ, Sugimura J et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003;22(43): 6810-8
42. Furge KA, Dykema K, Petillo D et al. Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Can Urol Assoc J. 2007;1(2 Suppl): S21-7.
43. Schuetz AN, Yin-Goen Q, Amin MB et al. Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 2005;7(2): 206-18
44. Yao M, Huang Y, Shioi K et al. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int J Cancer 2008;123(5): 1126-32
45. Yin-Goen Q, Dale J, Yang WL et al. Advances in molecular classification of renal neoplasms. Histol Histopathol 2006;21(3): 325-39
46. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69(3): 89-95
47. Ngo TC, Wood CG, Karam JA. Biomarkers of renal cell carcinoma. Urol Oncol 2014;32(3): 243-51
48. Funakoshi T, Lee CH, Hsieh JJ. A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev 2014;40(4): 533-47
49. Oldenhuis CN, Oosting SF, Gietema JA, de Vries EG. Prognostic versus predictive value of biomarkers in oncology. Eur J Cancer 2008 May;44(7): 946-53
50. Nogueira M, Kim HL. Molecular markers for predicting prognosis of renal cell carcinoma. Urol Oncol 2008;26(2): 113-24
51. Garraway LA, Lander ES. Lessons from the cancer genome. Cell 2013;153(1): 17-37
52. Purdue MP, Johansson M, Zelenika D et al. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nature genetics 2011;43(1): 60-5
53. Wu X, Scelo G, Purdue MP et al. A genome-wide association study identifies a novel susceptibility locus for renal cell carcinoma on 12p11.23. Human molecular genetics 2012;21(2): 456-62
54. Brannon AR, Haake SM, Hacker KE et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. European urology 2012;61(2): 258-68
55. Dondeti VR, Wubbenhorst B, Lal P et al. Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets. Cancer research 2012;72(1): 112-21
56. Alves G, Pereira DA, Sandim V et al. Urine screening by Seldi-Tof, followed by biomarker identification, in a Brazilian cohort of patients with renal cell carcinoma (RCC). International Braz J Urol 2013;39(2): 228-39. Epub 2013/05/21
57. Takahashi M, Rhodes DR, Furge KA et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proceedings of the National Academy of Sciences of the United States of America 2001;98(17): 9754-9. Epub 2001/08/09
58. Zhao H, Ljungberg B, Grankvist K, Rasmuson T, Tibshirani R, Brooks JD. Gene expression profiling predicts survival in conventional renal cell carcinoma. PLoS medicine 2006;3(1):e13. Epub 2005/12/02
59. Sanjmyatav J, Steiner T, Wunderlich H, Diegmann J, Gajda M, Junker K. A specific gene expression signature characterises metastatic potential in clear cell renal cell carcinoma. The Journal of urology 2011(186): 289-94
60. Beroukhim R, Brunet JP, Di Napoli A et al. Patterns of gene expression and copy-number alterations in von-Hippel Lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer research 2009;69(11): 4674-81
61. Girgis AH, Iakovlev VV, Beheshti B et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer research 2012;72(20): 5273-84
62. Eichelberg C, Chun FK, Bedke J et al. Epithelial cell adhesion molecule is an independent prognostic marker in clear cell renal carcinoma. Int J Cancer 2013;132(12): 2948-55
63. Sanford T, Chung PH, Reinish A et al. Molecular sub-classification of renal epithelial tumors using meta-analysis of gene expression microarrays. PloS one 2011;6(7): e21260
64. van Haaften G, Dalgliesh GL, Davies H et al. Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet 2009;41(5): 521-3
65. Yoshimoto T, Matsuura K, Karnan S et al. High-resolution analysis of DNA copy number alterations and gene expression in renal clear cell carcinoma. J Pathol 2007;213(4): 392-401. Epub 2007/10/09
66. Guo G, Gui Y, Gao S et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012;44(1): 17-9
67. Dalgliesh GL, Furge K, Greenman C, Chen L, Bignell G, Butler A, et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010;463(7279): 360-3
68. Linehan WM. Genetic basis of kidney cancer: role of genomics for the development of diseasebased therapeutics. Genome Res 2012;22(11): 2089-100
69. Fitzgerald JP, Nayak B, Shanmugasundaram K et al. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One. 2012;7(1): e30712
70. Sonpavde G, Choueiri TK. Precision medicine for metastatic renal cell carcinoma. Urol Oncol 2014;32(1): 5-15
71. Zeng Z, Que T, Zhang J, Hu Y. A study exploring critical pathways in clear cell renal cell carcinoma. Experimental and therapeutic medicine 2014;7(1): 121-30
72. Aaronson DS, Horvath CM. A road map for those who know JAK-STAT. Science 2002(296): 1653-5
73. Wei J, Li Z, Yuan F. Evodiamine inhibition of TGF-beta1-induced epithelial-mesenchymal transition in NRK52E cells via Smad and PPAR-gamma pathway. Cell Biol Int 2014. doi: 10.1002/cbin.10270
74. Penzvalto Z, Tegze B, Szasz AM et al. Identifying resistance mechanisms against five tyrosine kinase inhibitors targeting the ERBB/RAS pathway in 45 cancer cell lines. PloS One 2013;8(3): e59503
75. Furge KA, Dykema K, Petillo D et al. Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma. Canadian Urological Association Journal 2007;1(2 Suppl): S21-7
76. Nabti I, Marangos P, Bormann J, Kudo NR, Carroll J. Dual-mode regulation of the APC/C by CDK1 and MAPK controls meiosis I progression and fidelity. The Journal of Cell Biology 2014;204(6): 891-900
77. Darwish OM1, Kapur P, Youssef RF et al. Cumulative number of altered biomarkers in mammalian target of rapamycin pathway is an independent predictor of outcome in patients with clear cell renal cell carcinoma. Urology 2013;81(3):581-6
78. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18(16): 1926-45
79. Shuch B, Amin A, Armstrong AJ et al. Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity. Eur Urol. 2014; doi: 10.1016/ j.eururo. 2014.04.029.
80. Ricketts CJ, Linehan WM. Intratumoral heterogeneity in kidney cancer. Nat Genet. 2014 ;46(3): 214-5
81. Bex A, Etto T, Vyth-Dreese F, Blank C, Griffioen AW. Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response? Curr Oncol Rep 2012 Jun;14(3): 230-9.
82. Vogelstein B, Papadopoulos N, Velculescu VE et al. Cancer genome landscapes. Science 2013 29;339(6127): 1546-58
83. Sottoriva A, Spiteri I, Shibata D, Curtis C, Tavaré S. Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. Cancer Res 2013 1;73(1): 41-9
84. Shah SP, Morin RD, Khattra J et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009;8;461(7265): 809-13
85. Nik-Zainal S, Alexandrov LB, Wedge DC et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 25;149(5):979-93
86. Gerlinger M, Rowan AJ, Horswell S et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine. 2012;366(10): 883-92. Epub 2012/03/09
87. Kreso A1, O'Brien CA, van Galen P et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Science 2013 1;339(6119):543-8
88. Fisher R, Pickering L, Larkin J. New targeted therapies for renal cell carcinoma. Expert Opin Investig Drugs 201;20(7): 933-45
89. Swanton C, Larkin JM, Gerlinger Met al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome medicine 2010; 2(8): 53. Epub 2010/08/13
90. Lane BR, Li J, Zhou M et al. Differential expression in clear cell renal cell carcinoma identified by gene expression profiling. The Journal of Urology 2009;181(2): 849-60. Epub 2008/12/20
91. Wuttig D, Zastrow S, Fussel S et al. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases. Int J Cancer 2012;131(5): E693-704. Epub 2012/01/04
92. Brooks SA, Brannon AR, Parker JS et al. ClearCode34: A Prognostic Risk Predictor for Localized Clear Cell Renal Cell Carcinoma. European Urology 2014. Epub 2014/03/13
93. Wozniak MB, Le Calvez-Kelm F, Abedi-Ardekani B et al. Integrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United States. PloS One. 2013;8(3): e57886. Epub 2013/03/26
94. Kosari F, Parker AS, Kube DM et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005;11(14): 5128-39. Epub 2005/07/22
95. Tan W, Hildebrandt MA, Pu X et al. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. The Journal of Urology. 2011;186(5): 2071-7. Epub 2011/09/29
96. Mizumori O, Zembutsu H, Kato Y et al. Identification of a set of genes associated with response to interleukin-2 and interferon-alpha combination therapy for renal cell carcinoma through genome-wide gene expression profiling. Experimental and therapeutic medicine 2010;1(6): 955-61. Epub 2010/11/01
97. Voss MH, Hakimi AA, Pham CG et al. Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clin Cancer Res 2014;20(7): 1955-64. Epub 2014/03/14
98. Gamez-Pozo A, Anton-Aparicio LM, Bayona C et al. MicroRNA expression profiling of peripheral blood samples predicts resistance to first-line sunitinib in advanced renal cell carcinoma patients. Neoplasia 2012;14(12): 1144-52. Epub 2013/01/12
99. Laird A, O'Mahony FC, Nanda J et al. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PloS One 2013;8(4): e60483
100. Escudier B. Emerging immunotherapies for renal cell carcinoma. Annals of Oncology 23 (Supplement 8), 2012; 35-40, doi:10.1093/annonc/mds261
101. Rosenblatt J, McDermott DF Immunotherapy for renal cell carcinoma. Hematol Oncol Clin North Am 2011;25(4): 793-812
102. Leppert JT, Pantuck AJ. Significance of gene expression analysis of renal cell carcinoma. Expert Rev Anticancer Ther 2006;6(2): 293-9
103. Stehle F, Schulz K, Seliger B. Towards defining biomarkers indicating resistances to targeted therapies. Biochimica et Biophysica Acta. 2013; 1844(5): 909-16
104. Jones J, Libermann TA. Genomics of renal cell cancer: the biology behind and the therapy ahead. Clin Cancer Res 2007;13(2 Pt 2): 685s-92s
105. Choueiri TK, Ye J, Sonpavde G et al. Incidence and risk of treatment-related mortality in patients with renal cell cancer (RCC) and non-RCC treated with mammalian target of rapamycin (mTOR) inhibitors. J Clin Oncol 31, 2013 (suppl 6; abstr 347)
106. Rini BI, Bowser A, Lazure P et al. Professional practice gaps and barriers to optimal care of renal cell carcinoma (RCC) among oncologists in the United States. J Clin Oncol 32, 2014 (suppl 4; abstr 404)
107. Maroto P, Rini B. Molecular biomarkers in advanced renal cell carcinoma. Clin Cancer Res. 2014 Apr 15;20(8):2060-71
108. Yeh CN, Chung WH, Su SC et al. Fas/Fas Ligand Mediates Keratinocyte Death in Sunitinib- Induced Hand-Foot Skin Reaction. J Invest Dermatol. 2014 May 6. doi: 10.1038/jid.2014.218
109. Escudier BJ, Porta C, Squires M, Szczylik C et al. Biomarker analysis from a phase III trial (GOLD) of dovitinib (Dov) versus sorafenib (Sor) in patients with metastatic renal cell carcinoma after one prior VEGF pathway-targeted therapy and one prior mTOR inhibitor therapy. J Clin Oncol 32, 2014 (suppl 4; abstr 473)
110. Choueiri TK, Figueroa DJ, Liu Y et al. Correlation of PDL1 tumor expression and treatment outcomes in patients with renal cell carcinoma (RCC) receiving tyrosine kinase inhibitors: COMPARZ study analysis. J Clin Oncol 32, 2014 (suppl 4; abstr 416)
111. Krabbe L-M, Westerman ME et al. Dysregulation of the beta-catenin complex as an independent predictor of oncological outcomes in patients with ccRCC. J Clin Oncol 32, 2014 (suppl 4; abstr 493)
112. Khoury MJ, Clauser SB, Freedman AN et al. Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev 2011 Oct;20(10): 2105-14
113. Simon R, Roychowdhury S. Implementing personalized cancer genomics in clinical trials. Nat Rev Drug Discov 2013 May;12(5): 358-69
114. Bloss CS, Schork NJ, Topol EJ. Effect of direct-to-consumer genomewide profiling to assess disease risk. N Engl J Med 2011 Feb 10;364(6): 524-34
115. Gwinn M, Grossniklaus DA, Yu W et al. Horizon scanning for new genomic tests. Genet Med. 2011 Fb;13(2): 161-5
116. Stadler ZK, Vijai J, Thom P. Genome-wide association studies of cancer predisposition. Hematol Oncol Clin North Am 2010 Oct;24(5): 973-96
117. Guttmacher AE, Porteous ME, McInerney JD. Educating health-care professionals about genetics and genomics. Nat Rev Genet 2007 Feb;8(2): 151-7
118. Brooks JD. Translational genomics: the challenge of developing cancer biomarkers. Genome Res 2012 Feb;22(2): 183-7
119. Tran B, Dancey JE, Kamel-Reid S et al. Cancer genomics: technology, discovery, and translation. J Clin Oncol 2012 Feb 20;30(6): 647-60
120. Ginsburg GS, Kuderer NM. Comparative effectiveness research, genomics-enabled personalized medicine, and rapid learning health care: a common bond. J Clin Oncol 2012 Dec 1;30(34): 4233-42
121. Cheng L, Zhang S, MacLennan GT. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol 2009;40(1): 10-29
122. Hakimi AA, Jacobsen A, Mikkilineni N et al. MicroRNA as novel blood-based biomarkers in clear cell renal cell carcinoma. J Clin Oncol 31, 2013 (suppl 6; abstr 375)
123. Aparicio LMA, Villaamil VM, Gallego GA et al. Molecular expression profiling and pathway analysis of formalin-fixed paraffin-embedded primary renal tumor specimens. J Clin Oncol 31, 2013 (suppl 6; abstr 448)
124. Hakimi AA, Ostrovnaya I, Voss MH et al. Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project. J Clin Oncol 31, 2013 (suppl 6; abstr 360)
125. Su D, Stamatakis L, Singer EA, Srinivasan R. Renal cell carcinoma: molecular biology and targeted therapy. Curr Opin Oncol 2014;26(3): 321-7
126. Garcia-Roig M, Ortiz N, Lokeshwar V. Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need? Curr Urol Rep 2014;15(1): 375
127. Schilsky RL. Implementing personalized cancer care. Nat Rev Clin Oncol 2014; doi: 10.1038/nrclinonc.2014.54
128. Hung FH, Chiu HW, Chang YC. Revealing pathway maps of renal cell carcinoma by gene expression change. Comput Biol Med 2014;51C:111-121. doi: 10.1016/j.compbiomed.2014.04.023
129. Zhao DP, Yang CL, Zhou X, Ding JA, Jiang GN. Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies. Mol Genet Genomics 2014 Jun 7 [Epub ahead of print]
130. Runge A, Hu J, Wieland M et al. An inducible hepatocellular carcinoma model for preclinical evaluation of anti-angiogenic therapy in adult mice. Cancer Res 2014 Jun 6. pii: canres.2311.2013
131. Sato M, Kadota M, Tang B et al. An integrated genomic approach identifies persistent tumor suppressive effects of transforming growth factor-beta in human breast cancer. Breast Cancer Res 2014 Jun 2;16(3):R57 [Epub ahead of print]
132. Berdiel-Acer M, Cuadras D, Guillen Diaz-Maroto N et al. A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression and Metastasis. Mol Cancer Res 2014 May 14. pii: molcanres.0121.2014
133. Kühn MW, Bullinger L, Gröschel S et al. Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. Haematologica 2014 May 23. pii: haematol.2014.105544]
134. VanderWeele DJ, Brown CD, Taxy JB et al. Low grade prostate cancer diverges early from high grade and metastatic disease. Cancer Sci 2014 May 31. doi: 10.1111/cas.12460
135. Hollingshead MG, Stockwin LH, Alcoser SY et al. Gene expression profiling of 49 human tumor xenografts from in vitro culture through multiple in vivo passages-strategies for data mining in support of therapeutic studies. BMC Genomics 2014;15:393. doi: 10.1186/1471-2164-15-393
136. Marrone M, Filipski KK, Gillanders EM, Schully SD, Freedman AN. Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. PLoS Curr 2014;27;6. doi: 10.1371/currents.eogt.aa5415d435fc886145bd7137a280a971
137. Dulbecco R. From genome to cancer-why the time is right. In: Collins FS, Barker D. Mapping the Cancer Genome. Scientific American 2007.
138. Garcia-Donas J, Rodriguez-Antona C, Jonasch E. Molecular markers to predict response to therapy. Semin Oncol 2013;40(4): 444-58
139. Xu J, Guo Z, Zhang J et al. Single nucleotide polymorphisms in the mitochondrial displacement loop and age-at-onset of renal cell carcinoma. Sci Rep 2013;3: 2408
140. Choueiri TK, Fay AP, Gagnon R et al. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res 2013;19(18): 5218-26
141. Zurita AJ, Jonasch E, Wang X et al. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2012;23(1):46-52
142. Albiges L, Guegan J, Le Formal A. MET is a potential target across all Papillary Renal Cell Carcinomas. Result from a large molecular study of pRCC with CGHa and matching Gene Expression array. Clin Cancer Res 2014 [Epub ahead of print]
143. Maishi N, Ohga N, Hida Y. CXCR7: a novel tumor endothelial marker in renal cell carcinoma. Pathol Int 2012;62(5): 309-17
144. Logan JE, Mostofizadeh N, Desai AJ. PD-0332991, a potent and selective inhibitor of cyclindependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity. Anticancer Res. 2013;33(8): 2997-3004
145. Fritz HK, Lindgren D, Ljungberg B, Axelson H, Dahlbäck B. The miR21/10b ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer 2014. pii: S0959-8049(14)00563-2
146. Eggers H, Steffens S, Grosshennig A et al. Prognostic and diagnostic relevance of hypermethylated in cancer 1 (HIC1) CpG island methylation in renal cell carcinoma. Int J Oncol 2012;40(5): 1650-8
147. Lin A, Piao HL, Zhuang L et al. FoxO transcription factors promote AKT Ser473 phosphorylation and renal tumor growth in response to pharmacologic inhibition of the PI3K-AKT pathway. Cancer Res 2014;74(6): 1682-93
148. Lee JO, Yang H, Georgescu MM et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999; 99(3):323-34
149. Kim DH, Sarbassov DD, Ali SM et al. GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003;11(4): 895- 904.
150. Kucejova B, Peña-Llopis S, Yamasaki T et al. Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma. Mol Cancer Res 2011;9(9): 1255-65